These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19135105)

  • 1. Ins and outs of the ABCG2 multidrug transporter: an update on in vitro functional assays.
    Hegedus C; Szakács G; Homolya L; Orbán TI; Telbisz A; Jani M; Sarkadi B
    Adv Drug Deliv Rev; 2009 Jan; 61(1):47-56. PubMed ID: 19135105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human ABC transporter ABCG2 in cancer chemotherapy: drug molecular design to circumvent multidrug resistance.
    Ishikawa T; Saito H; Hirano H; Inoue Y; Ikegami Y
    Methods Mol Biol; 2012; 910():267-78. PubMed ID: 22821599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the breast cancer resistance protein (ABCG2) in drug transport.
    Mao Q; Unadkat JD
    AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomic importance of ABCG2.
    Cusatis G; Sparreboom A
    Pharmacogenomics; 2008 Aug; 9(8):1005-9. PubMed ID: 18681776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters.
    Ivnitski-Steele I; Larson RS; Lovato DM; Khawaja HM; Winter SS; Oprea TI; Sklar LA; Edwards BS
    Assay Drug Dev Technol; 2008 Apr; 6(2):263-76. PubMed ID: 18205550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics.
    Ishikawa T; Nakagawa H
    J Exp Ther Oncol; 2009; 8(1):5-24. PubMed ID: 19827267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABCG2 -- a transporter for all seasons.
    Sarkadi B; Ozvegy-Laczka C; Német K; Váradi A
    FEBS Lett; 2004 Jun; 567(1):116-20. PubMed ID: 15165903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid regulation of the ABCB1 and ABCG2 multidrug transporters.
    Hegedüs C; Telbisz Á; Hegedűs T; Sarkadi B; Özvegy-Laczka C
    Adv Cancer Res; 2015; 125():97-137. PubMed ID: 25640268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete reversal of ABCG2-depending atypical multidrug resistance by RNA interference in human carcinoma cells.
    Priebsch A; Rompe F; Tönnies H; Kowalski P; Surowiak P; Stege A; Materna V; Lage H
    Oligonucleotides; 2006; 16(3):263-74. PubMed ID: 16978089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug resistance mediated by ABC transporters].
    Yoshikawa M; Ito A; Ishikawa T; Ikegami Y
    Gan To Kagaku Ryoho; 2004 Jan; 31(1):1-6. PubMed ID: 14750312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pharmacology of ABCG2 and its role in chemoresistance.
    Stacy AE; Jansson PJ; Richardson DR
    Mol Pharmacol; 2013 Nov; 84(5):655-69. PubMed ID: 24021215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Zhang H; Wang YJ; Zhang YK; Wang DS; Kathawala RJ; Patel A; Talele TT; Chen ZS; Fu LW
    Cancer Lett; 2014 Aug; 350(1-2):61-8. PubMed ID: 24747122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.
    Jani M; Ambrus C; Magnan R; Jakab KT; Beéry E; Zolnerciks JK; Krajcsi P
    Arch Toxicol; 2014 Jun; 88(6):1205-48. PubMed ID: 24777822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistance molecules: lessons from oncology.
    Scheffer GL; Scheper RJ
    Novartis Found Symp; 2002; 243():19-31; discussion 31-7, 180-5. PubMed ID: 11990777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2.
    Henriksen U; Gether U; Litman T
    J Cell Sci; 2005 Apr; 118(Pt 7):1417-26. PubMed ID: 15769853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).
    Meyer zu Schwabedissen HE; Kroemer HK
    Handb Exp Pharmacol; 2011; (201):325-71. PubMed ID: 21103975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCRP/ABCG2 inhibitors: a patent review (2009-present).
    Wiese M
    Expert Opin Ther Pat; 2015; 25(11):1229-37. PubMed ID: 26291461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology.
    Cervenak J; Andrikovics H; Ozvegy-Laczka C; Tordai A; Német K; Váradi A; Sarkadi B
    Cancer Lett; 2006 Mar; 234(1):62-72. PubMed ID: 16337740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
    To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
    Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.